Synonym
BN 52111; BN-52111; BN52111
IUPAC/Chemical Name
Pyridinium, 1-(6-((2-heptadecyl-2-methyl-1,3-dioxolan-4-yl)methoxy)-6-oxohexyl)-, bromide
InChi Key
YZHGMFNGBBTPOH-UHFFFAOYSA-M
InChi Code
InChI=1S/C33H58NO4.BrH/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-20-25-33(2)37-30-31(38-33)29-36-32(35)24-19-17-21-26-34-27-22-18-23-28-34;/h18,22-23,27-28,31H,3-17,19-21,24-26,29-30H2,1-2H3;1H/q+1;/p-1
SMILES Code
O=C(OCC1OC(C)(CCCCCCCCCCCCCCCCC)OC1)CCCCC[N+]2=CC=CC=C2.[Br-]
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
612.73
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Braquet P, Hosford D, Koltz P, Guilbaud J, Paubert-Braquet M. Effect of platelet-activating factor on tumor necrosis factor-induced superoxide generation from human neutrophils. Possible involvement of G proteins. Lipids. 1991 Dec;26(12):1071-5. PubMed PMID: 1668107.
2: Paubert-Braquet M, Hosford D, Klotz P, Guilbaud J, Braquet P. Tumor necrosis factor alpha 'primes' the platelet-activating factor-induced superoxide production by human neutrophils: possible involvement of G proteins. J Lipid Mediat. 1990;2 Suppl:S1-4. PubMed PMID: 1966810.
3: Pons F, Touvay C, Lejeune V, Carré C, Vilain B, Broquet C, Mencia-Huerta JM, Braquet P. Action of platelet-activating factor (PAF) antagonists on the bronchopulmonary effects of PAF in the guinea-pig. J Lipid Mediat. 1989 Nov-Dec;1(6):329-40. PubMed PMID: 2519901.
4: Mandi Y, Farkas G, Koltai M, Beladi I, Mencia-Huerta JM, Braquet P. The effect of the platelet-activating factor antagonist, BN 52021, on human natural killer cell-mediated cytotoxicity. Immunology. 1989 Jul;67(3):370-4. PubMed PMID: 2759659; PubMed Central PMCID: PMC1385355.
5: Thivierge M, Rola-Pleszczynski M. Enhancement of pulmonary natural killer cell activity by platelet activating factor. Mechanisms of activation involving Ca2+, protein kinase C, and lipooxygenase products. Am Rev Respir Dis. 1991 Aug;144(2):272-7. PubMed PMID: 1650153.
6: Domingo MT, Piro F, Broquet C, Auclair E, Chabrier PE, Braquet P. Reversible or irreversible modification of [3H]PAF binding on rabbit platelet membranes differentiates various PAF receptor antagonists. Lipids. 1992 Aug;27(8):582-6. PubMed PMID: 1328798.
